Abselion, a Cambridge, UK-based company which specializes in automated analytical instrumentation that simplifies at-line protein quantification, raised £6.6M in Series A funding.
The round was led by M Ventures, with participation from new investors BioProcess 360 Partners and Untitled Ventures, along with BGF, R42 and other existing investors. Oliver Hardick of M Ventures and Chris Major of BioProcess 360 Partners have joined the company’s new Board of Directors.
The company intends to use the funds to drive the commercialisation and expand the capabilities of its Amperia system.
Led by CEO Ruizhi Wang, Abselion is a company which specializes in automated analytical instrumentation simplifying at-line protein analytics for the development and production of biologics, such as antibodies and viral vectors. With its sensitive and specific, redox-electrochemical-detection (RED) technology, the company seeks to streamline and accelerate access to process insights in biopharmaceutical research, development and production.
This benchtop instrument allows scientists to quantify antibodies, AAVs, and other proteins directly from crude samples in as little as one minute, providing critical data on the spot, enhancing efficiency and accuracy in life science research and bioprocessing.
FinSMEs
09/12/2024